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Summary In a case control study of 287 women aged 15-24 years with malignant melanoma and 574
matched controls, findings relating to oral contraceptive use and other hormone use are reported. Ever having
used oral contraceptives was not associated with an increased risk of melanoma (relative risk for ever use of
the pill= 1.0). Women with melanoma were, however, more likely to have taken oral contraceptives for long
periods of time in the past, the relative risk associated with oral contraceptive use for a total duration of 5
years or longer which had begun at least 10 years before the melanoma was diagnosed being 1.5 (95%
confidence interval 1.03 to 2.14) This elevated risk persisted after controlling for the reported hair and skin
colour, frequency of moles on the body, place of birth, and measures of sunlight and fluorescent light
exposure. Cases were more likely than controls to have used hormones to regulate their periods, hormonal
replacement therapy and be given hormone injections to suppress lactation, the respective relative risks being
1.9, 1.4 and 1.4, but none differed significantly from 1.0. These findings suggest that prolonged oral
contraceptive use may, after a lag of 10 years or so, increase the risk of malignant melanoma.
A number of recent studies have reported on the
relationship between past oral contraceptive use
and malignant melanoma (Beral et al., 1977;
Ramcharan et al., 1981; Adam et al., 1981; Kay,
1981; Bain et al., 1982; Holly et al., 1983). Most
reported a weak association or none at all for
melanoma and ever having used oral
contraceptives. In contrast, however, all four which
examined data on prolonged oral contraceptive use
reported an increased risk associated with long term
pill use (Beral et al., 1977; Adam et al., 1981; Bain
et al., 1982; Holly et al., 1983), although the
increase was not always statistically significant. We
report here the findings of a case control study
carried out in New South Wales, Australia,
designed to examine these relationships.
Methods
The study design has been described elsewhere
(Beral et al., 1982). Briefly, 287 white women
attending the melanoma clinic at Sydney Hospital
aged 18-54 years and 574 age-matched controls
were interviewed by trained interviewers using a
standard questionnaire. The diagnosis of melanoma
was by biopsy and histological features were classi-
fied by the late Prof. V.J. McGovern. Two hundred
and thirteen cases were "old cases" whose
melanoma was diagnosed between 1974 and June
1978, when our study began. Another 87 women
eligible for inclusion as old cases were not
interviewed: 40 had died and 3 were too ill to be
interviewed; 16 lived in very remote areas; 16 could
not be traced; 4 refused to take part; and another 8
were not interviewed for a variety of reasons. The
other 74 "new cases" were interviewed between
June 1978 and December 1980. Two age-matched
controls were chosen for each case. Controls for
"old cases" were matched by area of residence and
chosen from the general population; controls for
"new cases" were selected from hospital inpatients,
but excluded women admitted with any vascular
disease or gynaecological disorder, diabetes,
gallbladder or breast disease, rheumatoid arthritis,
mental illness, or any chronic disease of more than
2 years' duration. The questionnaire included
questions about demographic and social factors.
Each woman was also asked detailed questions
about her pregnancy history, and about use of oral
contraceptives and of other female sex hormones.
For each case the number of pregnancies she
reported and the total months that she had used
oral contraceptives up to the date of diagnosis of
her melanoma was calculated; for the controls,
number of pregnancies and oral contraceptive use
was calculated up to a corresponding date. Data
were analysed using the computing facilities at
London University, and relative risks (RRs), chi-
squared tests for trend and Mantel-Haenszel
adjusted RRs estimated using the calculator
programs of Rothman & Boice (1979).
Results
The age distribution of cases was similar. The
respective percentages aged 18-24 years were 14.3%
and 14.3%; 24-35 years 32.1% and 33.6%; 35-44
years 35.2% and 34.8%; and 45-54 years 18.5%
and 17.2%. A similar proportion (28%) of cases
and controls had never used oral contraceptives
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(Table I). A greater proportion of women with
melanoma had taken oral contraceptives for more
than 5 years (29.3% versus 24.3%), but this
difference was not significantly different. Among
those who had taken the pill, a greater percentage
of cases than controls had begun taking the pill at
least 10 years earlier (46.6% compared with 38.5%,
X2=3.8, P=0.05) Since total duration of oral
contraceptive use is closely correlated with the time
since first taking the pill, we examined the data
simultaneously for these two factors. The only
group in which there was a consistently increased
risk of melanoma was in those who had begun
taking the pill at least 10 years before, and who
had taken it for a total duration of 5 years or
longer (RR=1.5, 95% confidence interval 1.03 to
2.14). Roughly similar relationships were found for
"new" cases and "old" cases, as is shown in Table
II, and so most analyses pool the two groups. Our
other analyses of these data have related melanoma
to a number of factors (Beral et al., 1982, 1983).
We therefore stratified the findings for oral
contraceptives by a large number of possible
confounding factors. After adjusting for marital
status, hair colour, skin colour, eye colour, country
of birth, number of moles on the body, educational
status, exposure to fluorescent light, history of
cholasma, extent of outdoor activity at ages 10, 20,
30 and 40 years, and history of sunburning various
parts of the body, the relative risks associated with
pill use for 5 years or more which began at least 10
years ago fluctuated between 1.43 and 1.58 and
remained statistically significantly elevated. There
was no significant difference in the site of the
lesion, the tumour thickness nor the tumour type in
women who had used the pill and those who had
not (Table III).
Data on the use of other female sex hormones
are shown in Table IV. The numbers reported to
have ever used any of these is small, but the
proportions of cases who reported that they used
each was higher than the corresponding figures for
the controls. The RRs and 95% confidence
intervals for use of hormones to regulate periods
was 1.9 (0.85-4.12). for hormones replacement
therapy 1.4 (0.78-2.61) and for hormones to
suppress lactation 1.3 (0.92-1.82).
Data on oral contraceptive use had been
recorded for old cases on the melanoma clinic
records before this survey began. The findings from
our special survey agreed well with the distribution
of duration of contraceptive use recorded in the
clinic notes (Table V). Furthermore, data from the
clinic records on oral contraceptive use in the 87
women who were eligible but not interviewed in
this survey, showed that their contraceptive use was
also similar to that of the other women (Table V).
Table I Reported oral contraceptive use in cases
and controls
Total duration of Cases Controls
oral contraceptive use no. (%) no. (%)
Never 79(27.5) 159(27.8)
1-11 months 29(10.1) 73(12.8)
1-4 years 95(33.1) 201(35.1)
5-9 years 56(19.5) 103(18.0)
10+ years 28 (9.8) 36 (6.3)
Total 287(100) 572(100)a
aData missing for 2 controls.
Table II Reported duration of oral contraceptive use in
"new" and "old" cases and in their corresponding
controls
Oral "New" "Old"
contraceptive cases Controls cases Controls
use no. (%) no. (%) no. (%) no. (%)
Use for a total
duration of 5 years
or longer, beginning
at.least 10 years
before diagnosis 18(24) 21(14) 41(19) 64(15)
Other use 40(54) 80(54) 109(51) 248(58)
Never use 16(22) 47(32) 63(30) 112(26)
74(100) 148(100) 213(100) 424(100)
Discussion
The findings presented here indicate after a lag of
10 years oral contraceptive use for a total of 5
years or longer was associated with a 50% increase
in risk (RR= 1.5, 95% confidence limits 1.03-2.14).
This relationship persisted after adjusting for a
number of potential confounding factors, including
complexion, sunbathing activities, occupation and
education.
Our data on oral contraceptive use are unlikely
to be biased. For old cases they agree closely with
that which was recorded in the melanoma clinic
records before this survey began. Furthermore, the
distribution of oral contraceptive use in the 87
women who had died, could not be traced, or were
not interviewed for a number of other reasons was
similar to that of those who were interviewed. Only
limited information about brand of oral
contraceptive was collected, and no marked
associations were noted.
These Australian findings on the relationship
between oral contraceptives and other hormones
are in general consistent with reports from the UK
and USA. All studies which have examined for an
association with long term pill use or for a possibleORAL CONTRACEPTIVES AND MELANOMA IN AUSTRALIA 683
Table III Site of melanoma, tumour thickness and histogenetic type,
according to reported oral contraceptive use. (Data on site of lesion missing
for 9 cases, on thickness missing for 105, and on tumour type missing for 45
cases.)
Tumour characteristics Oral contraceptive use
Total use of
5 years or more
beginning at
least 10 years Other Never Total
before diagnosis use use ( 100%)
Site
Head and neck 5(23) 10(45) 7(32) 22
Arms 13(25) 26(50) 13(25) 52
Legs 28(19) 70(48) 48(32) 146
Trunk 11(19) 40(69) 7(12) 58
Thickness
<0.5 mm 7(19) 23(62) 7(19) 37
0.51-1.00mm 17(23) 40(55) 16(22) 73
1.01-2.00mm 7(13) 31(57) 16(30) 54
>2.00mm 4(22) 7(39) 7(39) 18
Type
Superficial spreading 41(21) 107(55) 48(24) 196
Nodular 8(19) 25(60) 9(21) 42
Hutchinson's melanotic
freckle 0(0) 2(50) 2(50) 4
All 59(20.5) 149(51.9) 79(27.5) 287(100)
Percentages in parentheses.
Table IV Reported use of various types of hormones in
cases and controls and estimated relative risk
Cases Controls Relative
number(%) number(%) risk
Use ofhormones to
regulate periods 12(4.1) 13(2.3) 1.9
Use ofhormone
replacement therapy 19(6.6) 27(4.7) 1.4
Use ofhormonal
injections to
suppress lactation
(ever pregnant
women only 93(43.7) 173(36.3) 1.4
lag effect, have noted an increase in risk, although
the numbers of cases in other studies were often
small. The findings of the various studies are
summarised in Table VI. Relative risk estimates
reported by us or others for long duration of oral
contraceptive use are in the range of 1.4 to 4.4.
These relative risks are not particularly large, but
they are of the same order of magnitude as the
relative risks associated with characteristics such as
blonde hair colour (RR=1.6) or fair skin
(RR=2.1), noted by us for the Australian women
(Beral et al., 1983). Both these factors are widely
accepted as being important determinants of
melanoma.
Data on the use of female sex hormones, other
than oral contraceptives, also tends to show a weak
association with melanoma. In California the
relative risk associated with other oestrogen use
was 1.8 (Beral et al., 1977); in Washington State it
was approximately 1.0 (Holly et al., 1983); in684 V. BERAL et al.
Table V Comparison of duration of oral contraceptive use reported in our
survey and that recorded in clinic notes
213 old cases interviewed 87 women eligible
both in the clinic and in for our survey but
our survey not interviewed
Duration oforal Reported in Recorded in Recorded in
contraceptive use our survey clinic notes clinic notes
Never use 63(30) 68(32) 24(29)
Total duration
<5 y 89(42) 80(38) 40(48)
Total duration
.5 y 61(29) 62(30) 20(24)
Missing 0 3 3
Percentages in parentheses.
Table VI Summary of findings from different studies on melanoma
and oral contraceptive use
Relative risk
Long term use of
Ever use oforal oral contraceptives
contraceptives versus shorter term
versus never use use or never uset
Case control studies
Beral et al. (1) 1.9 No data
Adam et al. (3)* 1.1 1.6
Adam et al. (3)t 1.34 1.4
Bain et al. (5) 0.93 3.0*
Holly et al. (6) 1.15 4.4*
This study 1.0 1.5*
Cohort studies
Beral et al. (1) 1.4 1.7
Adam et al. (3) 0.3 No data
Kay et al. (4) 1.5 No data
Ramcharan et al. (2) 3.5* No data
*Differs significantly from 1.0 (P<O.OS).
tLong term use: definitions.
Beral et al.: total duration of use of4+ years.
Adam et al. : total duration of use of 5+ years; a=data from
postal survey; b=data from GP records.
Bain et al.: total duration of use of 2+ years beginning 10+
years before diagnosis.
Holly et al.: total duration of use of 5+ years beginning 12+
years before diagnosis (superficial spreading
melanoma only).
This study: total duration of use of 5+ years, beginning 10+
years before diagnosis.ORAL CONTRACEPTIVES AND MELANOMA IN AUSTRALIA 685
England, 1.4 (Adam et al., 1981), and in our
study the figure was 1.6. While none is statistically
significant, all except for the Washington data show
a consistent increase in risk.
While oral contraceptives and other exogenous
sex hormones are clearly not major determinants of
melanoma, the accumulating evidence suggests that
they may increase the risk ofdisease. If, as our data
and that of others suggest, a lag period of 10 years
or more is involved, it may still be several decades
before the effect of oral contraceptives on
malignant melanoma can be properly evaluated.
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